FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296532704> ?p ?o ?g. }

• W4296532704 endingPage "S386" @default.
• W4296532704 startingPage "S385" @default.
• W4296532704 abstract "Treatment options for patients with R/R FL or MZL are limited. Tafasitamab is an Fc-engineered humanized monoclonal antibody against CD19, which is broadly expressed in FL and MZL and regulates B-cell proliferation. Tafasitamab monotherapy showed clinical activity in a phase 2a study (NCT01685008), with an ORR of 29% (n/N=10/34) and 33% (n/N=3/9) in patients with FL and MZL, respectively. In an ongoing phase 2 study (L-MIND, NCT02399085), tafasitamab plus lenalidomide (LEN) followed by tafasitamab alone demonstrated an ORR of 57.5% (n/N=46/80) in patients with R/R diffuse large B-cell lymphoma (FDA approved indication). These observations suggest potential clinical benefit of tafasitamab plus LEN for patients with R/R FL or MZL.To investigate efficacy and safety of tafasitamab plus LEN as add-on to rituximab compared with LEN alone added to rituximab in patients with R/R FL or MZL.Multicenter, global, randomized, double-blind, placebo-controlled, phase 3 study.≥18 years with histologically confirmed FL (grade 1, 2, or 3a) or MZL (nodal, splenic, or extranodal), documented R/R disease, ≥1 prior systemic anti-CD20 therapy (including anti-CD20 refractory disease), ECOG PS ≤2, high tumor burden (per GELF criteria). Exclusions include prior rituximab plus LEN combination treatment, history of non-hematologic malignancy, congestive heart failure, or known CNS lymphoma. inMIND (NCT04680052, EudraCT2020-004407-13) is currently enrolling, with planned enrollment of 528 R/R FL and 60-90 R/R MZL patients.Patients will be randomized 1:1 to receive tafasitamab (12 mg/kg IV on days 1, 8, 15, and 22 of a 28-day cycle [cycles 1-3], then days 1 and 15 [cycles 4-12]) plus LEN (20 mg PO QD, days 1-21/cycle for 12 cycles) and rituximab (375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1, then day 1 of cycles 2-5) OR placebo (0.9% saline solution IV) plus LEN and rituximab.Primary endpoint is PFS (investigator-assessed [INV] by Lugano 2014 criteria) for patients with FL. Secondary endpoints include PFS (INV) in the overall population, PET-CR rate (INV) at 90 days after last treatment, and OS in patients with FL." @default.
• W4296532704 created "2022-09-21" @default.
• W4296532704 creator A5004025497 @default.
• W4296532704 creator A5010206363 @default.
• W4296532704 creator A5015230787 @default.
• W4296532704 creator A5016803459 @default.
• W4296532704 creator A5023107894 @default.
• W4296532704 creator A5026641386 @default.
• W4296532704 creator A5057795879 @default.
• W4296532704 creator A5062765976 @default.
• W4296532704 creator A5066232993 @default.
• W4296532704 creator A5072124785 @default.
• W4296532704 creator A5075743939 @default.
• W4296532704 creator A5084791226 @default.
• W4296532704 creator A5088476247 @default.
• W4296532704 date "2022-10-01" @default.
• W4296532704 modified "2023-10-12" @default.
• W4296532704 title "IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)" @default.
• W4296532704 doi "https://doi.org/10.1016/s2152-2650(22)01552-x" @default.
• W4296532704 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36164102" @default.
• W4296532704 hasPublicationYear "2022" @default.
• W4296532704 type Work @default.
• W4296532704 citedByCount "0" @default.
• W4296532704 crossrefType "journal-article" @default.
• W4296532704 hasAuthorship W4296532704A5004025497 @default.
• W4296532704 hasAuthorship W4296532704A5010206363 @default.
• W4296532704 hasAuthorship W4296532704A5015230787 @default.
• W4296532704 hasAuthorship W4296532704A5016803459 @default.
• W4296532704 hasAuthorship W4296532704A5023107894 @default.
• W4296532704 hasAuthorship W4296532704A5026641386 @default.
• W4296532704 hasAuthorship W4296532704A5057795879 @default.
• W4296532704 hasAuthorship W4296532704A5062765976 @default.
• W4296532704 hasAuthorship W4296532704A5066232993 @default.
• W4296532704 hasAuthorship W4296532704A5072124785 @default.
• W4296532704 hasAuthorship W4296532704A5075743939 @default.
• W4296532704 hasAuthorship W4296532704A5084791226 @default.
• W4296532704 hasAuthorship W4296532704A5088476247 @default.
• W4296532704 hasConcept C126322002 @default.
• W4296532704 hasConcept C143998085 @default.
• W4296532704 hasConcept C2776063141 @default.
• W4296532704 hasConcept C2776364478 @default.
• W4296532704 hasConcept C2777058707 @default.
• W4296532704 hasConcept C2779338263 @default.
• W4296532704 hasConcept C2780653079 @default.
• W4296532704 hasConcept C31760486 @default.
• W4296532704 hasConcept C535046627 @default.
• W4296532704 hasConcept C71924100 @default.
• W4296532704 hasConcept C90924648 @default.
• W4296532704 hasConceptScore W4296532704C126322002 @default.
• W4296532704 hasConceptScore W4296532704C143998085 @default.
• W4296532704 hasConceptScore W4296532704C2776063141 @default.
• W4296532704 hasConceptScore W4296532704C2776364478 @default.
• W4296532704 hasConceptScore W4296532704C2777058707 @default.
• W4296532704 hasConceptScore W4296532704C2779338263 @default.
• W4296532704 hasConceptScore W4296532704C2780653079 @default.
• W4296532704 hasConceptScore W4296532704C31760486 @default.
• W4296532704 hasConceptScore W4296532704C535046627 @default.
• W4296532704 hasConceptScore W4296532704C71924100 @default.
• W4296532704 hasConceptScore W4296532704C90924648 @default.
• W4296532704 hasLocation W42965327041 @default.
• W4296532704 hasLocation W42965327042 @default.
• W4296532704 hasOpenAccess W4296532704 @default.
• W4296532704 hasPrimaryLocation W42965327041 @default.
• W4296532704 hasRelatedWork W2126113018 @default.
• W4296532704 hasRelatedWork W2268151149 @default.
• W4296532704 hasRelatedWork W2892169260 @default.
• W4296532704 hasRelatedWork W2979596396 @default.
• W4296532704 hasRelatedWork W3168899802 @default.
• W4296532704 hasRelatedWork W3212793078 @default.
• W4296532704 hasRelatedWork W3214210779 @default.
• W4296532704 hasRelatedWork W4296533012 @default.
• W4296532704 hasRelatedWork W4310120157 @default.
• W4296532704 hasRelatedWork W4310125614 @default.
• W4296532704 hasVolume "22" @default.
• W4296532704 isParatext "false" @default.
• W4296532704 isRetracted "false" @default.
• W4296532704 workType "article" @default.